Free Trial
TSE:ONC

Oncolytics Biotech 3/7/2024 Earnings Report

Oncolytics Biotech logo
C$0.53 -0.03 (-5.36%)
As of 01:00 PM Eastern

Oncolytics Biotech EPS Results

Actual EPS
-C$0.05
Consensus EPS
-C$0.15
Beat/Miss
Beat by +C$0.10
One Year Ago EPS
N/A

Oncolytics Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncolytics Biotech Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncolytics Biotech Earnings Headlines

HC Wainwright Has Weak Estimate for TSE:ONC FY2028 Earnings
HC Wainwright Has Pessimistic Outlook of TSE:ONC Q2 Earnings
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Oncolytics Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email.

About Oncolytics Biotech

Oncolytics Biotech (TSE:ONC), a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

View Oncolytics Biotech Profile

More Earnings Resources from MarketBeat